Common Variable Immunodeficiency clinical trials at UCSF
1 research study open to eligible people
Common variable immunodeficiency is a condition where the immune system doesn't work properly. UCSF is recruiting for a clinical trial called "Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease". This trial is for patients with a rare lung disease called GLILD and aims to find better treatment options.
open to eligible people ages 4 years and up
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD
San Francisco, California and other locations
Our lead scientists for Common Variable Immunodeficiency research studies include Michele Pham, MD.